Speak With Our Pharmaceutical ExecutivesConsider Value Genome your in-house market access and pricing team. We are well-versed in many areas of Oncology and Rare Diseases, and we want nothing more than to utilize our expertise to guide you toward a bright, successful path. To learn more, please feel free to get in touch with us.
Edward Dow is a highly experienced Physician Executive/Hematologist-Oncologist with expertise in Global and USA Medical Affairs as well as Clinical Development providing data generation and synthesis for medical support of new product commercialization
Starting at Millennium Takeda, Ed was the lead for US Medical Affairs on Velcade, the perennial blockbuster drug for multiple myeloma, and then later at Baxalta-Shire, he was the Global Med Affairs Launch Lead for Vonvendi, the first-ever recombinant therapy for Von Willebrand Disease. In both roles, he was extremely versatile providing medical leadership and support for MSL teams, Commercial/Market Access, Health Economics and Outcomes Research, Payer Relations, as well as Health Policy, Government Affairs, and Patient Advocacy.
At Foundation Medicine Inc., he helped create a Medical Affairs Team to aid in clinical adoption and reimbursement of genomic profiling in routine clinical practice leading up to CMS recognition of Foundation One, and Foundation One Heme.
In addition, he develops and runs First In Human Clinical Trials for cancer immunotherapies and sickle cell anemia. A lifelong resident of Boston, he attended Harvard College and the Tufts Medical School before sub-specialty training in Hematology-Oncology at Tufts Medical Center, Massachusetts General Hospital including special training in bone marrow transplantation at Fred Hutchinson Cancer Research Center, Seattle, WA.
With over twenty years of full-time patient care experience, he continues to practice seeing patients with cancer and blood diseases on a part-time basis in a community setting - dealing very much on the front-lines with issues patients face with access to state of the art medicines and therapy.
Office/Fax: 617-690-2161 | Edward.Dow@ValueGenome.com
Edward Dow is on Linkedin at www.linkedin.com/in/edward-dow-med
Jennifer King is a Partner at Value Genome. She brings a wealth of commercial and access experience across oncology and orphan drugs. She has worked in Global, EMEA and Asia Pacific/Japan markets in Pricing & Market Access. She plays an active role in advising clients on pricing and market access strategies with the goal of achieving optimal access for all stakeholders. Her extensive industry experience across therapeutic areas and geographies ensures clients benefits from that knowledge in both strategic development and implementation.
In her last position, Jennifer was Head of Pricing & Market Access at Celgene where she led the successful reimbursement of all Celgene products in the Asia Pacific Region including Japan. She also led the Global launch of Abraxane in mBC and NSCLC as the Head of Market Access for Solid Tumor. Jennifer has over 20 years of pricing and market access experience and worked for Amgen, Pfizer and Merck prior to Celgene.
Jennifer has a B.A. in Biochemistry from University of California, Berkeley and a MBA from Lehigh University.
(1) 908-451-8242 | Jennifer.King@ValueGenome.com
Jennifer King is on Linkedin at www.linkedin.com/in/jennifer-t-king
Kevin Mayo is Managing Partner of Value Genome LLC. Kevin is a member of MIT’s NEWDIG’s Financing and Reimbursing Cures in the US (FoCUS) multi-stakeholder target area groups for cellular and gene therapies where he serves on a working group designing performance based annuity payment contracts.
Earlier in his career Kevin gained industry and consulting expertise in senior leadership roles with Value Genome, Baxalta, The Access Partnership, Endo Health Solutions, Bridgehead International, Daiichi Sankyo, Novartis Pharma AG, Pharmacia Corporation, AstraZeneca and Jazz.
Kevin completed a Master’s degree in Neuropsychology and a Doctoral degree in Pharmaceutical Marketing and Administration. More recently Kevin augmented his business education by completing an Executive Juris Doctorate in Health Law and Policy. He has served on the adjunct faculties for the Mayes College of Healthcare Business and Policy (University of the Sciences) and the College of Population Health (Thomas Jefferson University) and is a frequent presenter at international market access conferences. Kevin received a Distinguish Service Award from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for his contribution to the society.
(1) 781-752-9804 | Kevin.Mayo@ValueGenome.com
Kevin Mayo is on Linkedin at www.linkedin.com/in/kevinmayomarketaccess
Joseph Rubino is a veteran market access, reimbursement and government affairs expert with interests in diagnostic and medical device strategy, HEOR and payer/provider market research. He leads Value Genome's projects focused upon coding, coverage, payment, evidence generation, launch plans and value communication strategies.
Who We Are
Value Genome, LLC. is a team of pharmaceutical and biotech executives with extensive real-world industry experience who share a common passion for assisting biopharmaceutical innovators in maximizing the pricing and reimbursement potential of their assets. We combine our medical, pricing, and reimbursement expertise with our extensive payer relations and direct product launch experience.
- We collaborate with you in developing market access strategies by looking at the clinical development program through product launch and across your product life-cycle to reveal the CLINICAL and ECONOMIC VALUE of your asset as defined by key stakeholders.
- We achieve this by engaging external stakeholders at all levels of health care delivery:
- Government/Commercial Payers and Their Advisors
- Physicians and Their Professional Societies
- Healthcare and Insurance Networks
- Patients and Patient Advocacy Organizations
- Hospital and Treatment Centers
- Health Technology Assessment Agencies
- Ministry Officials
- Health Economic Thought Leaders
Strategic Collaborators and Advisors
Rapid Commercialization Partners, Inc. (RCP) is dedicated to accelerating commercial readiness for clinical-stage biotech companies and offers a foundational shift in how biotech companies can achieve commercial success and rapid time to value. Engaging a team of senior commercial leaders with comprehensive biotech experience and unparalleled proficiency in critical subject matter areas essential to support commercialization, RCP works provides strategic and executional expertise on critical decision points early in the commercialization process to build the commercial foundation, address observable inefficiency, and bring needed therapies to patients faster and with improved fiscal responsibility.
Stephen F Amato, Ph.D., MBA, RAC
Department Chair, Global Regulatory Affairs/Quality Assurance/ Advanced Manufacturering, Northeastern University
Joseph Eichenholz, MA
Chief US Value and Access Strategy Lead
Mark Rubino, R.Ph, M.B.A.
Retired, Former Chief Pharmacy Officer Value Genome LLC